Johnson & Johnson

ADCs continue to be the hot topic in big pharma. Prior to the announced J&J deal, last year alone saw 155 deals struck for the…

Akeega’s current predicted sales will experience only a slight increase as a result of its narrow label and fierce competition…

Market cap surged from $3.49 trillion during the first quarter (Q1) of 2023 to $3.56 trillion in Q2 2023

Both Johnson & Johnson and Pfizer criticised the changes by referencing the positive role of patents in incentivising their…

Dr Reed will join J&J on April 3, 2023, assuming responsibility for the company’s portfolio from Dr William Hait, who has…

J&J's teclistamab, branded as Tecvayli, is approved for treating adults with multiple myeloma that is hard to treat, or has…

The company said it expects some impact of inflation to ease next year but higher costs of inventory manufactured in 2022 could…

The termination notice comes about a week after J&J had initially informed Emergent of its intent to end the pact based on the…

Johnson & Johnson and Momenta Pharma lawsuit alleged infringement of two old patents associated with 20mg/ml and 40mg/ml…

The vaccine brought in $2.38 billion in sales last year